Preclinical Research
First-in-Human-Enabling Toxicology Programs: Common Misconceptions by Grace M. Furman
Nomination of a clinical candidate and subsequent conduct of toxicology studies to support a first-in-human (FIH) clinical trial is an exciting milestone for sponsors! While many are highly experienced drug discovery professionals, some may have limited, or even no experience, in early clinical development, including the critical toxicology studies required to successfully support a FIH trial.
The Year in Review 2025
First-Timer Perspectives on Attending the AALAS National Meeting, by Brandon Ossont and Jennifer Lakritz
The 76th annual American Association for Laboratory Animal Science (AALAS) National Meeting is a cornerstone event for the laboratory animal science community, bringing together researchers, veterinarians, technicians, and industry partners to share knowledge, i
Reflections on the ACT Annual Meeting: Where Science Meets Connection
The American College of Toxicology (ACT) Annual Meeting continues to be my favorite scientific event of the year, and for good reason.
ISSUE NO. 47 — Size Matters: The Sinclair Nanopig® as a Translational Non-Rodent Model in Preclinical Research
Drug developers and scientists are constantly looking for animal models that are cost effective, aligned with research goals, and allow for lower test article (TA) usage without sacrificing scientific integrity and regulatory approval.
In Issue 47 of The Altascientist, we take a closer look at what makes the Sinclair Nanopig® a scientifically appropriate and cost-effective non-rodent species for your preclinical programs, covering:
- the benefits and advantages of using minipig models
- test article usage comparison between Sinclair Nanopig® and canine models
- the history and regulatory acceptance of the Sinclair Nanopig®
- a case study on reduced emesis in the Sinclair Nanopig®
Minipigs in Preclinical Drug Development
In the continuum of preclinical drug development, the selection of appropriate animal models is crucial for providing the safety data that is required for a novel therapeutic to progress into clinical trials.
30 Years of Innovation in Drug Development: The Evolution of the Contract Research Organization
Over the past three decades, drug development has evolved rapidly—driven by new technologies, tighter timelines, and greater collaboration. CROs like Altasciences have transformed, shifting from service providers to strategic partners.